MaxCyte Inc
Change company Symbol lookup
Select an option...
MXCT MaxCyte Inc
NRUC National Rural Utilities Cooperative Finance Corp
UPS United Parcel Service Inc
BOLT Bolt Biotherapeutics Inc
EIX Edison International
EM Smart Share Global Ltd
WTW Willis Towers Watson PLC
DSU BlackRock Debt Strategies Fund Inc
TRTN-A Triton International Ltd
RNG RingCentral Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

MaxCyte, Inc. (MaxCyte) is a life sciences company. The Company is focused on advancing the discovery, development and commercialization of cell therapies. The Company provide cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. MaxCyte has developed and commercialized Flow Electroporation platform, which facilitates engineering of a wide variety of cells. The Company's ExPERT platform, which is based on Flow Electroporation technology, is designed to address the expanding cell therapy market, and used across the continuum of the cell therapy sector. The ExPERT family of products includes: three instruments, the ATx, STx and GTx. MaxCyte has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

Closing Price
$6.05
Day's Change
0.05 (0.83%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.42
Day's Low
5.77
Volume
(Average)
Volume:
445,050

10-day average volume:
429,624
445,050

Company Profile

MaxCyte, Inc. (MaxCyte) is a life sciences company. The Company is focused on advancing the discovery, development and commercialization of cell therapies. The Company provide cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. MaxCyte has developed and commercialized Flow Electroporation platform, which facilitates engineering of a wide variety of cells. The Company's ExPERT platform, which is based on Flow Electroporation technology, is designed to address the expanding cell therapy market, and used across the continuum of the cell therapy sector. The ExPERT family of products includes: three instruments, the ATx, STx and GTx. MaxCyte has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
2.48x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

January 2022
Current Month
3.0M
Previous Month
3.4M
Percent of Float
3.55%
Days to Cover
7.6755 Days

Share Information

MXCT is in a share class of common stock
Float
87.7M
Shares Outstanding
101.5M
Institutions Holding Shares
128
79.44%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.